• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Clinical features of hepatitis B virus-related hepatocellular carcinoma.乙型肝炎病毒相关性肝细胞癌的临床特征。
World J Gastroenterol. 2010 May 28;16(20):2463-7. doi: 10.3748/wjg.v16.i20.2463.
2
Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.乙型肝炎病毒相关肝细胞癌的预防与监测
Semin Liver Dis. 2005;25 Suppl 1:40-7. doi: 10.1055/s-2005-915649.
3
Hepatitis B viral load affects prognosis of hepatocellular carcinoma.乙肝病毒载量影响肝细胞癌的预后。
World J Gastroenterol. 2014 Sep 14;20(34):12039-44. doi: 10.3748/wjg.v20.i34.12039.
4
The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.HBV 在肝癌中的直接和间接作用：HCC 筛查的前瞻性标志物和潜在治疗靶点。
J Pathol. 2015 Jan;235(2):355-67. doi: 10.1002/path.4434.
5
Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma.围手术期抗病毒治疗慢性乙型肝炎相关肝细胞癌。
Hepatobiliary Pancreat Dis Int. 2013 Jun;12(3):251-5. doi: 10.1016/s1499-3872(13)60041-7.
6
Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma.预测乙型肝炎病毒相关性肝细胞癌发生和预后的因素。
World J Gastroenterol. 2011 Oct 14;17(38):4258-70. doi: 10.3748/wjg.v17.i38.4258.
7
Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma.抗病毒治疗对乙型肝炎相关肝细胞癌肝切除术后结局的影响。
World J Gastroenterol. 2014 May 28;20(20):6006-12. doi: 10.3748/wjg.v20.i20.6006.
8
Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma.抗病毒治疗以降低乙型肝炎病毒相关肝细胞癌的复发率和提高生存率。
World J Gastroenterol. 2013 Dec 21;19(47):8861-6. doi: 10.3748/wjg.v19.i47.8861.
9
Prevention of hepatocellular carcinoma in hepatitis B virus infection.预防乙型肝炎病毒感染中的肝细胞癌
J Gastroenterol Hepatol. 2009 Aug;24(8):1352-7. doi: 10.1111/j.1440-1746.2009.05985.x.
10
Hepatitis B Virus Pre-S Mutants as Biomarkers and Targets for the Development and Recurrence of Hepatocellular Carcinoma.乙型肝炎病毒前 S 突变作为肝癌发生和复发的生物标志物和靶点。
Viruses. 2020 Aug 26;12(9):945. doi: 10.3390/v12090945.

引用本文的文献

1
The role of the hepatitis B virus genome and its integration in the hepatocellular carcinoma.乙型肝炎病毒基因组及其整合在肝细胞癌中的作用。
Front Microbiol. 2024 Sep 6;15:1469016. doi: 10.3389/fmicb.2024.1469016. eCollection 2024.
2
Outcomes of adolescent and young patients with hepatocellular carcinoma after curative liver resection: a retrospective study.青少年和年轻肝细胞癌患者根治性肝切除术后的结果：一项回顾性研究。
World J Surg Oncol. 2022 Jun 21;20(1):210. doi: 10.1186/s12957-022-02658-3.
3
HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC).HBV 基因组富集单细胞测序揭示了 HBV 驱动的肝细胞癌 (HCC) 的异质性。
BMC Med Genomics. 2022 Jun 16;15(1):134. doi: 10.1186/s12920-022-01264-2.
4
Long-term oncological prognosis after curative-intent liver resection for hepatocellular carcinoma in the young versus the elderly: multicentre propensity score-matching study.根治性肝切除术后青年与老年肝细胞癌患者的长期肿瘤学预后：多中心倾向评分匹配研究。
BJS Open. 2022 Jan 6;6(1). doi: 10.1093/bjsopen/zrab145.
5
Long-read sequencing reveals the structural complexity of genomic integration of HBV DNA in hepatocellular carcinoma.长读长测序揭示了肝细胞癌中HBV DNA基因组整合的结构复杂性。
NPJ Genom Med. 2021 Oct 12;6(1):84. doi: 10.1038/s41525-021-00245-1.
6
Adenovirus Vectors Expressing Eight Multiplex Guide RNAs of CRISPR/Cas9 Efficiently Disrupted Diverse Hepatitis B Virus Gene Derived from Heterogeneous Patient.腺病毒载体表达 CRISPR/Cas9 的八个多重引导 RNA 可有效破坏来自不同患者的乙型肝炎病毒基因。
Int J Mol Sci. 2021 Sep 29;22(19):10570. doi: 10.3390/ijms221910570.
7
C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism.C 末端截短的 HBx 通过下调 TXNIP 和重编程葡萄糖代谢引发肝癌发生。
Oncogene. 2021 Feb;40(6):1147-1161. doi: 10.1038/s41388-020-01593-5. Epub 2020 Dec 15.
8
Prognosis Factors of Young Patients Undergoing Curative Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma: A Multicenter Study.乙型肝炎病毒相关肝细胞癌行根治性切除的年轻患者的预后因素：一项多中心研究
Cancer Manag Res. 2020 Jul 30;12:6597-6606. doi: 10.2147/CMAR.S261368. eCollection 2020.
9
Studies on the correlation between mutation and integration of HBV in hepatocellular carcinoma.关于乙型肝炎病毒（HBV）突变与肝癌整合相关性的研究。
Biosci Rep. 2020 Aug 28;40(8). doi: 10.1042/BSR20201988.
10
Multiple novel hepatocellular carcinoma signature genes are commonly controlled by the master pluripotency factor OCT4.多个新型肝癌特征基因通常受多能性主调控因子 OCT4 控制。
Cell Oncol (Dordr). 2020 Apr;43(2):279-295. doi: 10.1007/s13402-019-00487-3. Epub 2019 Dec 17.

本文引用的文献

1
Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients.慢性丙型肝炎患者肝细胞癌消融治疗后采用干扰素治疗进行复发的二级预防。
World J Gastroenterol. 2008 Oct 28;14(40):6140-4. doi: 10.3748/wjg.14.6140.
2
Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.拉米夫定抗病毒治疗对乙型肝炎病毒相关肝细胞癌初始治疗后的疗效。
J Gastroenterol Hepatol. 2007 Nov;22(11):1929-35. doi: 10.1111/j.1440-1746.2006.04707.x.
3
Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study.采用依托泊苷、卡铂、表柔比星动脉内化疗联合5-氟尿嘧啶及替加氟/尿嘧啶肠溶制剂进行药代动力学调节化疗治疗伴有门静脉癌栓的肝细胞癌的生存改善：一项前瞻性研究。
World J Gastroenterol. 2007 Nov 7;13(41):5465-70. doi: 10.3748/wjg.v13.i41.5465.
4
The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence.接受经动脉化疗栓塞术的肝细胞癌患者中，乙肝病毒载量对完全坏死术后复发的影响：对病毒抑制以降低癌症复发风险的意义。
Cancer. 2007 Oct 15;110(8):1760-7. doi: 10.1002/cncr.22984.
5
Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus.拉米夫定对乙型肝炎病毒复制活跃的肝细胞癌患者肝切除术后结局的影响。
Hepatol Res. 2007 Feb;37(2):94-100. doi: 10.1111/j.1872-034X.2007.00013.x.
6
Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis.干扰素降低乙型肝炎病毒相关性肝硬化患者手术切除或消融肝细胞癌后的肿瘤复发率：一项前瞻性研究
J Gastroenterol. 2006 Dec;41(12):1206-13. doi: 10.1007/s00535-006-1912-0. Epub 2007 Feb 6.
7
Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma.乙型和丙型肝炎病毒相关可切除肝细胞癌的临床病理差异
J Viral Hepat. 2007 Jan;14(1):64-9. doi: 10.1111/j.1365-2893.2006.00776.x.
8
Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial.术后干扰素α治疗可延缓乙肝相关肝细胞癌根治性切除术后患者的复发并提高总生存率：一项随机临床试验
J Cancer Res Clin Oncol. 2006 Jul;132(7):458-65. doi: 10.1007/s00432-006-0091-y. Epub 2006 Mar 24.
9
Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients.拉米夫定预防慢性乙型肝炎肝癌的疗效：2795 例多中心回顾性研究。
Hepatol Res. 2005 Jul;32(3):173-84. doi: 10.1016/j.hepres.2005.02.006. Epub 2005 Jul 18.
10
Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan.日本乙型肝炎病毒Ba、Bj或C基因型肝细胞癌患者的差异。
Intervirology. 2005;48(4):239-45. doi: 10.1159/000084601.

乙型肝炎病毒相关性肝细胞癌的临床特征。

Clinical features of hepatitis B virus-related hepatocellular carcinoma.

机构信息

Department of Gastroenterology and Hepatology, Saiseikai Niigata Second Hospital, Teraji 280-7, Niigata 950-1104, Japan.

出版信息

World J Gastroenterol. 2010 May 28;16(20):2463-7. doi: 10.3748/wjg.v16.i20.2463.

DOI:10.3748/wjg.v16.i20.2463
PMID:20503445
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2877175/
Abstract

Hepatocellular carcinoma (HCC) is a major cause of cancer death, and chronic hepatitis B is a serious worldwide problem. The epidemiology of HCC is distinctive. Hepatitis B virus (HBV) plays a major role in hepatocarcinogenesis. Prevention of HBV-related HCC is a key issue in current hepatology. This paper describes the prevention and clinical features of HBV-related HCC, along with a short review of the disease.

摘要

肝细胞癌（HCC）是癌症死亡的主要原因，而慢性乙型肝炎是一个全球性的严重问题。HCC 的流行病学特征独具特点。乙型肝炎病毒（HBV）在肝癌发生中起主要作用。预防 HBV 相关 HCC 是当前肝病学的一个关键问题。本文描述了 HBV 相关 HCC 的预防和临床特征，并对该疾病进行了简要回顾。